27 Apr 2020 - 30 Apr 2020
Postponed: SafeSciMET Course 3.5 - Mutagenesis and Carcinogenesis
The development of new chemical compounds holds the potential risk of harmful mutagenic and/or carcinogenic effects to humans. Minimizing these risks during drug development requires appropriate experimentation and expert knowledge whose basic principles will be delivered with this course. Special emphasis will be given to the biology of cancer formation, the identification of mutagens and carcinogens and their modes of action on the cellular, biochemical and molecular level. In silico methods prediction as well as animal test systems and tissue culture assays for carcinogenicity testing will be presented. Furthermore, the importance of responsibly estimating dose-dependent probabilities of mutagenic/carcinogenic effects (risk assessment) and the risk-benefit evaluation will be discussed.
SafeSciMET - European Modular Education and Training Programme in Safety Science for Medicines
University of Konstanz